The adjuvant effects of CpG motif and activated large number of activated-T lymphocytes on immunoresponses.

我们研究了CpG基序质粒与HIV-DNA疫苗联合免疫或将大量活化的T细胞转移给疫苗免疫的同系小鼠是否能增强特异性免疫应答。将富含CpG的质粒与DNA疫苗共同给予Balb/c小鼠显著增加了HIV特异性细胞介导的和体液免疫。含有最多拷贝数（20个CpG）的质粒是最有效的免疫增强剂。取正常BALB/c小鼠脾细胞，在抗小鼠CD 3抗体包被的培养瓶中，加入IL-2进行培养。流式细胞仪表型分析显示，该细胞群中约60%为CD 8 +/Thy1.2+细胞，18.5%为CD 4 +/Thy1.2+细胞，8.9%为CD 19+细胞。这些活化的细胞通过I. p.途径给用HIV-DNA疫苗免疫的小鼠。结果表明，DNA疫苗接种后2天转移活化的T细胞增强了特异性细胞和体液免疫。CpG基序质粒和转移活化的T淋巴细胞共同给药均显示出更强的佐剂活性。这些佐剂方法不仅可以在人群中诱导HIV介导的免疫应答，还可以诱导其他传染病介导的免疫应答。这些管理可能是临床上的好处，因为他们的简单，缺乏副作用和安全性。

We examined whether the co-administering the CpG motifs plasmid with HIV-DNA vaccine or the transfer of a large number of activated T cells to syngenic mice immunized with vaccine can augment the specific immune responses. Co-administering the CpG-enriched plasmids with a DNA vaccine to Balb/c mice significantly increased HIV-specific cell mediated and humoral immunity. Plasmids containg a most of number of copies (20 CpG) were the most effective immune enhancers. Spleen cells from normal BALB/c were cultured with IL-2 in the anti-mouse CD3 Ab-coated flask. The number of lymphocytes increased about 10-fold.Phenotyping analysis by flow cytometry showed, this cell population contained about 60% of CD8+/Thy1.2+, 18.5% of CD4+/Thy1.2 + and 8.9% of CD19 + cells. These activated cells were transferred via the I. p. route to mice immunized with HIV-DNA vaccine. Results indicated that transfer activated T cells 2 days after DNA vaccination increased specific cellular and humoral immunity. Both co-administering the CpG motif plasmid and the transfer activated T lymphocytes showed stronger adjuvant activity. These adjuvant methods may induce not only HIV-mediated immune responses but also other infectious diseases-mediated immune responses in the human population as well. These administrations are likely to be of clinical benefit because their simplicity, lack of side effects and safety.